Projecting #Pharmaceutical Expenditure in #EU5 to 2021: Adjusting for the Impact of Discounts and Rebates https://t.co/Vh48IvMsYC
@AElshaug In case of interest, we published a couple of years ago something to illustrate potential impact of (known) discounts in EU5..still a big info gap, but impact can be significant... https://t.co/8gpk9fPuyS
@borisazais @sanofi Agreed the term 'price' is used too loosely, and we should be more precise when making remarks about their levels and changes! For more info on impact of discounts in EU5, we have this paper: https://t.co/8gpk9fPuyS
@GiraudSylvain "7sur7"? What's the Index Factor? I humbly advise reading: "Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates" https://t.co/rNrWTMjNe6 https://t.co/dtFY8oXbRX
#OECD Spesa #farmaceutica 2010-2015 in #italia cresce più di altri paesi europei effetto del trattamento anti #HCV o forse di una diversa contrattazione centrale? https://t.co/BH0haHyM6f @patriziabab @DArpinoDarpino @signorellicarlo @Cartabellotta @Manubon
RT @JorgeMestreFerr: what wonderful news to start the year! always nice to read such things...now let's hope we can do something about it!…
RT @JorgeMestreFerr: what wonderful news to start the year! always nice to read such things...now let's hope we can do something about it!…
RT @ApplHealthEcon: This was the most read paper in AHEHP in 2018, despite being published in the second half of the year! https://t.co/S3Q…
Great work @JorgeMestreFerr 👍👍🌷
RT @ApplHealthEcon: This was the most read paper in AHEHP in 2018, despite being published in the second half of the year! https://t.co/S3Q…
what wonderful news to start the year! always nice to read such things...now let's hope we can do something about it! ;) thanks of course to co-authors @jaime_net Thanks again @ApplHealthEcon for the excellent and swift review last year. Probably one of th
RT @ApplHealthEcon: This was the most read paper in AHEHP in 2018, despite being published in the second half of the year! https://t.co/S3Q…
RT @ApplHealthEcon: This was the most read paper in AHEHP in 2018, despite being published in the second half of the year! https://t.co/S3Q…
This was the most read paper in AHEHP in 2018, despite being published in the second half of the year! https://t.co/S3QuWPNVCi @JorgeMestreFerr
#healthcare sustainability
Bis 2021 werden in Deutschland die #Arzneimittelkosten jährlich um rund 2% steigen, so eine neue Europastudie: https://t.co/WiLWqnnju8 Die #Kostenexplosion ist also nur ein Mythos.
RT @BiblioEASP: #Produccioncientifica @EASPsalud Projecting #PharmaceuticalExpenditure in EU5 to 2021: Adjusting for the Impact of Discount…
RT @BiblioEASP: #Produccioncientifica @EASPsalud Projecting #PharmaceuticalExpenditure in EU5 to 2021: Adjusting for the Impact of Discount…
#Produccioncientifica @EASPsalud Projecting #PharmaceuticalExpenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates #gastofarmaceutico #EASPdivulga @jaime_net https://t.co/bXIxQgaHvR
RT @JorgeMestreFerr: fantastic collaboration estimating impact of rebates/discounts on pharma expenditure for EU5. It seems pharma expendit…
RT @JorgeMestreFerr: fantastic collaboration estimating impact of rebates/discounts on pharma expenditure for EU5. It seems pharma expendit…
RT @JorgeMestreFerr: fantastic collaboration estimating impact of rebates/discounts on pharma expenditure for EU5. It seems pharma expendit…
RT @JorgeMestreFerr: fantastic collaboration estimating impact of rebates/discounts on pharma expenditure for EU5. It seems pharma expendit…
fantastic collaboration estimating impact of rebates/discounts on pharma expenditure for EU5. It seems pharma expenditure is actually under control...let's make sure we implement the right policies to make that expenditure as efficient as possible! https:
#HealthEconJA Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates https://t.co/g0O5Q9A9DK